113 related articles for article (PubMed ID: 15552800)
1. New targeted treatments in lung cancer--overview of clinical trials.
Korfee S; Gauler T; Hepp R; Pöttgen C; Eberhardt W
Lung Cancer; 2004 Aug; 45 Suppl 2():S199-208. PubMed ID: 15552800
[TBL] [Abstract][Full Text] [Related]
2. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
6. New developments in chemotherapy for advanced non-small cell lung cancer.
Raez LE; Lilenbaum R
Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
[TBL] [Abstract][Full Text] [Related]
7. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
8. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
9. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
11. Targeting novel and established therapies for non-small cell lung cancer.
Spicer J; Chowdhury S; Harper P
Cancer Lett; 2007 May; 250(1):9-16. PubMed ID: 17030089
[TBL] [Abstract][Full Text] [Related]
12. Second and third line treatment in non-small cell lung cancer.
Favaretto A; Pasello G; Magro C; Schettino C; Gridelli C
Crit Rev Oncol Hematol; 2009 Aug; 71(2):117-26. PubMed ID: 19249227
[TBL] [Abstract][Full Text] [Related]
13. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
14. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitors in the treatment of lung cancer.
Sun S; Schiller JH
Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective.
Sasidharan R; Gibbs D; Sullivan R; Simpson A; Perez D; Christmas T; McKeage M
N Z Med J; 2006 Nov; 119(1245):U2310. PubMed ID: 17146485
[TBL] [Abstract][Full Text] [Related]
17. Methodological aspects of lung cancer clinical trials in the era of targeted agents.
Di Maio M; Gallo C; De Maio E; Morabito A; Piccirillo MC; Gridelli C; Perrone F
Lung Cancer; 2010 Feb; 67(2):127-35. PubMed ID: 19875193
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
19. Clinical drug development: an analysis of phase II trials, 1970-1985.
Marsoni S; Hoth D; Simon R; Leyland-Jones B; De Rosa M; Wittes RE
Cancer Treat Rep; 1987 Jan; 71(1):71-80. PubMed ID: 3791270
[TBL] [Abstract][Full Text] [Related]
20. Conclusions: future strategies in the treatment of breast cancer.
Piccart MJ; Hortobagyi GN
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S34-40. PubMed ID: 9071339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]